NANOBIOTIX Announces Positive New Pre-clinical Data Suggesting Radioenhancer NBTXR3 Could Have a Significant Impact in Immunotherapy

Excerpt from the Press Release:

PARIS & CAMBRIDGE, Mass.–(BUSINESS WIRE)–NANOBOTIX (Euronext: NANO – ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced positive new in vivo pre-clinical data from two (2) studies at The Society for Immunotherapy of Cancer (SITC) 35^th Anniversary Annual Meeting. One ePoster presentation was delivered by Nanobiotix and one oral presentation was delivered by The University of Texas MD Anderson Cancer Center (MD Anderson).

Historically, data has shown that radiation therapy can modulate the immune system; however, clinical evidence of distant tumor control and sustained antitumor immunity is rare. As such, there is an opportunity for new treatment solutions with the potential to prime a strong anti-tumor response. If validated, this benefit could improve treatment outcomes for patients receiving radiation therapy alone and could also be combined with immune checkpoint inhibitors (ICIs) such as anti-PD-1 and anti-CTLA to improve response rates and survival outcomes.

Click the button below to continue reading the Press Release:

Continue Reading The Press Release